Market Overview:
The global hepatitis B therapeutics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of hepatitis B, rising awareness about available treatments, and growing demand for better therapies. The global hepatitis B therapeutics market is segmented on the basis of type into vaccines and anti-viral drugs. The vaccines segment is further sub-segmented into monovalent and combination vaccines. The anti-viral drugs segment is further sub-segmented into interferon alpha, pegylated interferon alpha, nucleoside analogues, and protease inhibitors. On the basis of application, the market is divided into hospital pharmacies, retail pharmacies, online pharmacies,. Geographically,,the global hepatitis B therapeutics market has been segmented into North America,,Latin America,,Europe,,Asia Pacific,,and Middle East & Africa (MEA). North America dominates the global hepatitsis B therapeutics Market due to high prevalence rate of HBV infections in countries such as Uinted States and Canada .
Product Definition:
Hepatitis B is a virus that causes inflammation of the liver. It can lead to cirrhosis, liver cancer, and death. There is no cure for hepatitis B, but there are treatments available that can help keep the virus under control. Treatment options include antiviral medications and lifestyle changes such as diet and exercise.
Hepatitis B Vaccine:
Hepatitis B is an inflammation of liver tissue caused by the Hepatitis virus (HBV or HCV). The disease can be acute (lasting a few weeks) or chronic (last for months to years), depending on the degree of liver damage. Acute hepatitis B can result in jaundice, abdominal pain, and fatigue; while chronic hepatitis B may lead to elevated blood pressure, diabetes mellitus, and liver cancer.
Anti-viral Drugs:
Anti-viral drugs are used to treat viral infections such as Hepatitis B and C. Anti-viral drugs act by either preventing the virus from reproducing or by killing the viruses already present in the body. Viruses can be classified into two types: those that are contagious and can reproduce only inside living cells (endogenous viruses) and those that are noncontagious but can survive outside living cells (exogenous viruses).
Application Insights:
Based on application, the global hepatitis B therapeutics market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacy held the largest share of over 60.0% in 2017 owing to its ability to provide immediate treatment for a patient with a viral infection of the liver such as HBV. Hospital based pharmacist are better equipped to handle complex cases that require multiple antiviral drugs at once which may not be feasible in other settings such as outpatient clinics or primary healthcare centers (PHCs).
The growing prevalence of chronic diseases such as cancer and diabetes along with increasing geriatric population across the globe has led to an increased demand for effective & efficient medicines that cure rather than just treat symptoms thereby driving this segment further during forecast period.
Regional Analysis:
North America dominated the global hepatitis B therapeutics market in 2017. This can be attributed to the presence of a large number of manufacturers, rising prevalence of chronic diseases, and increasing healthcare expenditure in this region. The U.S., which is at the forefront, accounted for more than 75% share owing to high prevalence and incidence rates coupled with favorable government initiatives such as vaccination programs and raising awareness drives growth in this region.
Asia Pacific is expected to witness lucrative growth over the forecast period due to factors such as improving economic conditions leading to rise in disposable income levels; growing target population base; increase adoption by individuals for self-treatment; improvement & introduction of infrastructure facilities for conducting clinical trials; increase investment by governments & private players coupled with low manufacturing cost compared to developed regions making it an attractive destination for drug manufacturers/suppliers thus driving revenue generation opportunities throughout the forecast period.
Growth Factors:
- Increasing incidence of hepatitis B infections across the globe
- Growing demand for better and more effective therapies for hepatitis B treatment
- Rising awareness about the benefits of early diagnosis and treatment of hepatitis B infections
- increasing number of clinical studies on new potential therapies for hepatitis B5. growing investment in research and development activities for novel treatments for hepatitis
Scope Of The Report
Report Attributes
Report Details
Report Title
Hepatitis B Therapeutics Market Research Report
By Type
Hepatitis B Vaccine, Anti-viral Drugs
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
GlaxoSmithKline, Bristol-Myers Squibb, Novira Therapeutics, Johnson & Johnson, Abivax, F. Hoffmann- La Roche, Novartis, Merck
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
132
Number of Tables & Figures
93
Customization Available
Yes, the report can be customized as per your need.
Global Hepatitis B Therapeutics Market Report Segments:
The global Hepatitis B Therapeutics market is segmented on the basis of:
Types
Hepatitis B Vaccine, Anti-viral Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Bristol-Myers Squibb
- Novira Therapeutics
- Johnson & Johnson
- Abivax
- F. Hoffmann- La Roche
- Novartis
- Merck
Highlights of The Hepatitis B Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hepatitis B Vaccine
- Anti-viral Drugs
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hepatitis B Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hepatitis B therapeutics are medications used to treat hepatitis B. These medications help the body fight off the virus and restore normal liver function.
Some of the major players in the hepatitis b therapeutics market are GlaxoSmithKline, Bristol-Myers Squibb, Novira Therapeutics, Johnson & Johnson, Abivax, F. Hoffmann- La Roche, Novartis, Merck.
The hepatitis b therapeutics market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hepatitis B Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hepatitis B Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hepatitis B Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hepatitis B Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hepatitis B Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Hepatitis B Therapeutics Market Size and Y-o-Y Growth
4.5.2 Hepatitis B Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Hepatitis B Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Hepatitis B Therapeutics Market Size Forecast by Type
5.2.1 Hepatitis B Vaccine
5.2.2 Anti-viral Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Hepatitis B Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Hepatitis B Therapeutics Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hepatitis B Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hepatitis B Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Hepatitis B Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Hepatitis B Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Hepatitis B Therapeutics Market Size Forecast by Type
9.6.1 Hepatitis B Vaccine
9.6.2 Anti-viral Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Hepatitis B Therapeutics Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Hepatitis B Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Hepatitis B Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Hepatitis B Therapeutics Market Size Forecast by Type
10.6.1 Hepatitis B Vaccine
10.6.2 Anti-viral Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Hepatitis B Therapeutics Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Hepatitis B Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Hepatitis B Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Hepatitis B Therapeutics Market Size Forecast by Type
11.6.1 Hepatitis B Vaccine
11.6.2 Anti-viral Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Hepatitis B Therapeutics Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Hepatitis B Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Hepatitis B Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Hepatitis B Therapeutics Market Size Forecast by Type
12.6.1 Hepatitis B Vaccine
12.6.2 Anti-viral Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Hepatitis B Therapeutics Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Hepatitis B Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Hepatitis B Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Hepatitis B Therapeutics Market Size Forecast by Type
13.6.1 Hepatitis B Vaccine
13.6.2 Anti-viral Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Hepatitis B Therapeutics Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hepatitis B Therapeutics Market: Competitive Dashboard
14.2 Global Hepatitis B Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline
14.3.2 Bristol-Myers Squibb
14.3.3 Novira Therapeutics
14.3.4 Johnson & Johnson
14.3.5 Abivax
14.3.6 F. Hoffmann- La Roche
14.3.7 Novartis
14.3.8 Merck
